Cytarabine
- Product NDC
- 61703-155
- 11-digit product format
- 617030155
- Labeler code
- 61703
- Product ID
- 61703-155_e3a8c0e9-19ed-49b7-8464-11e8806f47fd
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- CYTARABINE
- Dosage form
- INJECTION, SOLUTION
- Route
- INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS
- Labeler
- Hospira, Inc.
- Application
- ANDA075383
- Marketing category
- ANDA
- Marketing start
- 2025-04-07
- Substance
- CYTARABINE
- Active strength
- 100 mg/mL
- Pharmacologic classes
- Nucleic Acid Synthesis Inhibitors [MoA], Nucleoside Metabolic Inhibitor [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Cytarabine
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| CYTARABINE | 100 mg/mL |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 04079A1RDZ |
| Rxcui | 249364 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 61703-155-01 | Cytarabine | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | | 1 |
| 61703-155-01 | Cytarabine | 1 in 1 CARTON | INJECTION, SOLUTION | 1 | | 1 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 61703-155 | CYTARABINE INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | Current NDC, 2 package rows | 20250420_e3a8c0e9-19ed-49b7-8464-11e8806f47fd.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|
| 61703-155-01 | 61703015501 | 1 VIAL, SINGLE-DOSE in 1 CARTON (61703-155-01) / 20 mL in 1 VIAL, SINGLE-DOSE | 2025-04-07 | No | No | Current |